Omega-3 polyunsaturated fatty acids as an angelus custos to rescue patients from NSAID-induced gastroduodenal damage

Journal of Gastroenterology

Volumn 50, Issue 6, 2015, Pages 614-625

  Park, Jong Min ^a   Han, Young Min ^a   Jeong, Migyeong ^a   Kim, Eun Hee ^a   Ko, Weon Jin ^a   Cho, Joo Young ^a   Hahm, Ki Baik ^a  

^a CHA University   (South Korea)

Author keywords

Gastrointestinal risk; Lipid raft; n 3 polyunsaturated fatty acid; n 3 polyunsaturated fatty acid based nonsteroidal anti inflammatory drug; Nonsteroidal anti inflammatory drug

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; ANTIOXIDANT; GLUCOSE REGULATED PROTEIN 78; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; X BOX BINDING PROTEIN 1;

ADVERSE DRUG REACTION; ANTIOXIDANT ACTIVITY; CAENORHABDITIS ELEGANS; CELL DEATH; CELL FUNCTION; CELL MEMBRANE FLUIDITY; CELLULAR STRESS RESPONSE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CYTOTOXICITY; DRUG MECHANISM; DRUG SAFETY; DUODENUM PERFORATION; ENDOPLASMIC RETICULUM STRESS; EPIGASTRIC PAIN; EPITHELIZATION; FAT 1 GENE; GAS CHROMATOGRAPHY; GENE; HEART INFARCTION; HUMAN; HYPERTENSION; LEUKOCYTE ADHERENCE; LIPID RAFT; LIPID STORAGE; META ANALYSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; NONSTEROIDAL ANTI INFLAMMATORY DRUG INDUCED GASTRODUODENAL DAMAGE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STOMACH DISEASE; STOMACH PROTECTION; STOMACH ULCER; THROMBOCYTE AGGREGATION; TRANSGENIC MOUSE; WATER RETENTION; ANIMAL; CELL MEMBRANE; CHEMICALLY INDUCED; DRUG EFFECTS; GASTROINTESTINAL DISEASES; METABOLISM; PEPTIC ULCER; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FATTY ACIDS, OMEGA-3; GASTROINTESTINAL DISEASES; HUMANS; MEMBRANE MICRODOMAINS; OXIDATIVE STRESS; PEPTIC ULCER; SIGNAL TRANSDUCTION;

EID: 84930756978     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-014-1034-z     Document Type: Review

References (107)

1. Curiel RV, Katz JD. Mitigating the cardiovascular and renal effects of NSAIDs. Pain Med. 2013;14(Suppl 1):S23–8.
2. Vonkeman HE, van de Laar MA. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum. 2010;39(4):294–312.
3. Gargallo CJ, Sostres C, Lanas A. Prevention and treatment of NSAID gastropathy. Curr Treat Options Gastroenterol. 2014;12(4):398–413.
4. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010;32(4):667–77.
5. Sostres C, Gargallo CJ, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. World J Gastroenterol. 2014;20(28):9439–50.
6. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S3.
7. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141(4):1314–22.e5.
8. Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134(4):937–44.
9. Coruzzi G, Venturi N, Spaggiari S. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed. 2007;78(2):96–110.
10. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105(1B):31S–8S.
11. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012;32(6):1491–502.
12. Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleveland Clin J Med. 2002;69(Suppl 1):SI53–8.
13. Ejaz P, Bhojani K, Joshi VR. NSAIDs and kidney. J Assoc Phys India. 2004;52:632–40.
14. Sandoval-Acuna C, Lopez-Alarcon C, Aliaga ME, Speisky H. Inhibition of mitochondrial complex I by various non-steroidal anti-inflammatory drugs and its protection by quercetin via a coenzyme Q-like action. Chem Biol Interact. 2012;199(1):18–28.
15. Li H, Hortmann M, Daiber A, Oelze M, Ostad MA, Schwarz PM, et al. Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. J Pharmacol Exp Ther. 2008;326(3):745–53.
16. Sharma JN, Jawad NM. Adverse effects of COX-2 inhibitors. Sci World J. 2005;5:629–45.
17. Fiorucci S, Santucci L, Distrutti E. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. Dig Liver Dis. 2007;39(12):1043–51.
18. Fiorucci S, Santucci L. Hydrogen sulfide-based therapies: focus on H2S releasing NSAIDs. Inflamm Allergy Drug Targets. 2011;10(2):133–40.
19. Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res. 2001;44(6):437–50.
20. Leone S, Ottani A, Bertolini A. Dual acting anti-inflammatory drugs. Curr Top Med Chem. 2007;7(3):265–75.
21. Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res. 2001;43(5):429–36.
22. Kangwan N, Park JM, Hahm KB. Development of GI-safe NSAID; progression from the bark of willow tree to modern pharmacology. Curr Opin Pharmacol. 2014;19C:17–23.
23. Kang JX, Wang J, Wu L, Kang ZB. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature. 2004;427(6974):504.
24. Kang JX. Fat-1 transgenic mice: a new model for omega-3 research. Prostaglandins Leukot Essent Fatty Acids. 2007;77(5–6):263–7.
25. Zheng H, Tang H, Liu M, He M, Lai P, Dong H, et al. Inhibition of endometrial cancer by n-3 polyunsaturated fatty acids in preclinical models. Cancer Prev Res (Phila). 2014;7(8):824–34.
26. Weylandt KH, Krause LF, Gomolka B, Chiu CY, Bilal S, Nadolny A, et al. Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-α. Carcinogenesis. 2011;32(6):897–903.
27. Xia S, Lu Y, Wang J, He C, Hong S, Serhan CN, et al. Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci U S A. 2006;103(33):12499–504.
28. Li J, Li FR, Wei D, Jia W, Kang JX, Stefanovic-Racic M, et al. Endogenous omega-3 polyunsaturated fatty acid production confers resistance to obesity, dyslipidemia, and diabetes in mice. Mol Endocrinol. 2014;28(8):1316–28.
29. Bellenger J, Bellenger S, Bataille A, Massey KA, Nicolaou A, Rialland M, et al. High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: inflammatory pathway inhibition. Diabetes. 2011;60(4):1090–9.
30. Cai A, Hutchison E, Hudson J, Kawashima Y, Komori N, Singh A, et al. Metabolic enrichment of omega-3 polyunsaturated fatty acids does not reduce the onset of idiopathic knee osteoarthritis in mice. Osteoarthritis Cartilage. 2014;22(9):1301–9.
31. Luo C, Ren H, Wan JB, Yao X, Zhang X, He C, et al. Enriched endogenous omega-3 fatty acids in mice protect against global ischemia injury. J Lipid Res. 2014;55(7):1288–97.
32. Hu X, Zhang F, Leak RK, Zhang W, Iwai M, Stetler RA, et al. Transgenic overproduction of omega-3 polyunsaturated fatty acids provides neuroprotection and enhances endogenous neurogenesis after stroke. Curr Mol Med. 2013;13(9):1465–73.
33. Lopez-Vicario C, Gonzalez-Periz A, Rius B, Moran-Salvador E, Garcia-Alonso V, Lozano JJ, et al. Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2014;63(2):344–55.
34. Kim EH, Bae JS, Hahm KB, Cha JY. Endogenously synthesized n-3 polyunsaturated fatty acids in fat-1 mice ameliorate high-fat diet-induced non-alcoholic fatty liver disease. Biochem Pharmacol. 2012;84(10):1359–65.
35. Lim K, Han C, Dai Y, Shen M, Wu T. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking β-catenin and cyclooxygenase-2. Mol Cancer Ther. 2009;8(11):3046–55.
36. Tsutsumi S, Gotoh T, Tomisato W, Mima S, Hoshino T, Hwang HJ, et al. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ. 2004;11(9):1009–16.
37. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27–42.
38. Chen ST, Thomas S, Gaffney KJ, Louie SG, Petasis NA, Schonthal AH. Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. Leuk Res. 2010;34(2):250–3.
39. Chiou SK, Tanigawa T, Akahoshi T, Abdelkarim B, Jones MK, Tarnawski AS. Survivin: a novel target for indomethacin-induced gastric injury. Gastroenterology. 2005;128(1):63–73.
40. Chiou SK, Mandayam S. NSAIDs enhance proteasomic degradation of survivin, a mechanism of gastric epithelial cell injury and apoptosis. Biochem Pharmacol. 2007;74(10):1485–95.
41. Farrugia G, Balzan R. The proapoptotic effect of traditional and novel nonsteroidal anti-inflammatory drugs in mammalian and yeast cells. Oxid Med Cell Longev. 2013;2013:504230.
42. Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol. 2006;6(4):414–20.
43. Arita M, Clish CB, Serhan CN. The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem Biophys Res Commun. 2005;338(1):149–57.
44. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196(8):1025–37.
45. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107(10):1170–84.
46. Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, Campbell E, et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem. 2007;282(13):9323–34.
47. Jung TW, Hwang HJ, Hong HC, Choi HY, Yoo HJ, Baik SH, et al. Resolvin D1 reduces ER stress-induced apoptosis and triglyceride accumulation through JNK pathway in HepG2 cells. Mol Cell Endocrinol. 2014;391(1–2):30–40.
48. Ohta M, Kawano H, Notsu T, Naba H, Imada K. Eicosapentaenoic acid attenuates statin-induced ER stress and toxicity in myoblast. Biochem Biophys Res Commun. 2012;424(2):301–7.
49. Begum G, Yan HQ, Li L, Singh A, Dixon CE, Sun D. Docosahexaenoic acid reduces ER stress and abnormal protein accumulation and improves neuronal function following traumatic brain injury. J Neurosci. 2014;34(10):3743–55.
50. Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl. 1989;163:24–31.
51. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology. 1997;112(3):1000–16.
52. Wallace JL, Vong L. NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs. Curr Opin Investig Drugs. 2008;9(11):1151–6.
53. Faust T, Redfern JS, Lee E, Feldman M. Effects of fish oil on gastric mucosal 6-keto-PGF1 alpha synthesis and ethanol-induced injury. Am J Physiol. 1989;257(1 Pt 1):G9–13.
54. Leung FW. Prostaglandins mediate fish oil protection against ethanol-induced gastric mucosal injury in rats. Dig Dis Sci. 1994;39(4):893.
55. Faust TW, Redfern JS, Podolsky I, Lee E, Grundy SM, Feldman M. Effects of aspirin on gastric mucosal prostaglandin E2 and F2 alpha content and on gastric mucosal injury in humans receiving fish oil or olive oil. Gastroenterology. 1990;98(3):586–91.
56. Bhattacharya A, Ghosal S, Bhattacharya SK. Effect of fish oil on offensive and defensive factors in gastric ulceration in rats. Prostaglandins Leukot Essent Fatty Acids. 2006;74(2):109–16.
57. Guzel C, Ulak G, Sermet A, Cicek R, Ulak M. Effect of fish oil on indometacin-induced gastric lesions in rats. Arzneimittelforschung. 1995;45(11):1172–3.
58. Manjari V, Das UN. Effect of polyunsaturated fatty acids on dexamethasone-induced gastric mucosal damage. Prostaglandins Leukot Essent Fatty Acids. 2000;62(2):85–96.
59. Ulak G, Cicek R, Sermet A, Guzel C, Ulak M, Denli O. Protective effect of fish oil against stress-induced gastric injury in rats. Arzneimittelforschung. 1995;45(11):1174–5.
60. Mayurasakorn K, Williams JJ, Ten VS, Deckelbaum RJ. Docosahexaenoic acid: brain accretion and roles in neuroprotection after brain hypoxia and ischemia. Curr Opin Clin Nutr Metab Care. 2011;14(2):158–67.
61. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376(9740):540–50.
62. Cho JY, Chi SG, Chun HS. Oral administration of docosahexaenoic acid attenuates colitis induced by dextran sulfate sodium in mice. Mol Nutr Food Res. 2011;55(2):239–46.
63. Asako H, Kubes P, Wallace J, Gaginella T, Wolf RE, Granger DN. Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol. 1992;262(5 Pt 1):G903–8.
64. Santucci L, Fiorucci S, Giansanti M, Brunori PM, Di Matteo FM, Morelli A. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. Gut. 1994;35(7):909–15.
65. Pineda-Pena EA, Jimenez-Andrade JM, Castaneda-Hernandez G, Chavez-Pina AE. Docosahexaenoic acid, an omega-3 polyunsaturated acid protects against indomethacin-induced gastric injury. Eur J Pharmacol. 2012;697(1–3):139–43.
66. Gil A. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother. 2002;56(8):388–96.
67. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21(6):495–505.
68. Fernandes E, Toste SA, Lima JL, Reis S. The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. Free Radic Biol Med. 2003;35(9):1008–17.
69. Costa D, Gomes A, Reis S, Lima JL, Fernandes E. Hydrogen peroxide scavenging activity by non-steroidal anti-inflammatory drugs. Life Sci. 2005;76(24):2841–8.
70. Yiannakopoulou E, Tiligada E. Protective effect of salicylates against hydrogen peroxide stress in yeast. J Appl Microbiol. 2009;106(3):903–8.
71. Herrero E, Ros J, Belli G, Cabiscol E. Redox control and oxidative stress in yeast cells. Biochim Biophys Acta. 2008;1780(11):1217–35.
72. Oh KW, Qian T, Brenner DA, Lemasters JJ. Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition. Toxicol Sci. 2003;73(1):44–52.
73. Battaglia V, Salvi M, Toninello A. Oxidative stress is responsible for mitochondrial permeability transition induction by salicylate in liver mitochondria. J Biol Chem. 2005;280(40):33864–72.
74. Raza H, John A, Benedict S. Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells. Eur J Pharmacol. 2011;668(1–2):15–24.
75. Giordano E, Visioli F. Long-chain omega 3 fatty acids: molecular bases of potential antioxidant actions. Prostaglandins Leukot Essent Fatty Acids. 2014;90(1):1–4.
76. Anderson EJ, Thayne K, Harris M, Carraway K, Shaikh SR. Aldehyde stress and up-regulation of Nrf2-mediated antioxidant systems accompany functional adaptations in cardiac mitochondria from mice fed n-3 polyunsaturated fatty acids. Biochem J. 2012;441(1):359–66.
77. Anderson EJ, Thayne KA, Harris M, Shaikh SR, Darden TM, Lark DS, et al. Do fish oil omega-3 fatty acids enhance antioxidant capacity and mitochondrial fatty acid oxidation in human atrial myocardium via PPARγ activation? Antioxid Redox Signal. 2014;21(8):1156–63.
78. Varming K, Schmidt EB, Svaneborg N, Moller JM, Lervang HH, Grunnet N, et al. The effect of n-3 fatty acids on neutrophil chemiluminescence. Scand J Clin Lab Invest. 1995;55(1):47–52.
79. Fisher M, Levine PH, Weiner BH, Johnson MH, Doyle EM, Ellis PA, et al. Dietary n-3 fatty acid supplementation reduces superoxide production and chemiluminescence in a monocyte-enriched preparation of leukocytes. Am J Clin Nutr. 1990;51(5):804–8.
80. Rees D, Miles EA, Banerjee T, Wells SJ, Roynette CE, Wahle KW, et al. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr. 2006;83(2):331–42.
81. Ishikado A, Morino K, Nishio Y, Nakagawa F, Mukose A, Sono Y, et al. 4-Hydroxy hexenal derived from docosahexaenoic acid protects endothelial cells via Nrf2 activation. PLoS One. 2013;8(7):e69415.
82. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature. 1972;240(5381):410–1.
83. Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med. 1995;1(2):154–8.
84. Manrique-Moreno M, Garidel P, Suwalsky M, Howe J, Brandenburg K. The membrane-activity of ibuprofen, diclofenac, and naproxen: a physico-chemical study with lecithin phospholipids. Biochim Biophys Acta. 2009;1788(6):1296–303.
85. Giraud MN, Motta C, Romero JJ, Bommelaer G, Lichtenberger LM. Interaction of indomethacin and naproxen with gastric surface-active phospholipids: a possible mechanism for the gastric toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs). Biochem Pharmacol. 1999;57(3):247–54.
86. Lichtenberger LM, Zhou Y, Dial EJ, Raphael RM. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J Pharm Pharmacol. 2006;58(11):1421–8.
87. Nunes C, Brezesinski G, Lima JL, Reis S, Lucio M. Synchrotron SAXS and WAXS study of the interactions of NSAIDs with lipid membranes. J Phys Chem B. 2011;115(24):8024–32.
88. Nunes C, Brezesinski G, Pereira-Leite C, Lima JL, Reis S, Lucio M. NSAIDs interactions with membranes: a biophysical approach. Langmuir ACS J Surfaces Colloids. 2011;27(17):10847–58.
89. Stillwell W, Wassall SR. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids. 2003;126(1):1–27.
90. Wassall SR, Brzustowicz MR, Shaikh SR, Cherezov V, Caffrey M, Stillwell W. Order from disorder, corralling cholesterol with chaotic lipids. The role of polyunsaturated lipids in membrane raft formation. Chem Phys Lipids. 2004;132(1):79–88.
91. Chapkin RS, McMurray DN, Davidson LA, Patil BS, Fan YY, Lupton JR. Bioactive dietary long-chain fatty acids: emerging mechanisms of action. Br J Nutr. 2008;100(6):1152–7.
92. Kim W, Fan YY, Barhoumi R, Smith R, McMurray DN, Chapkin RS. n-3 polyunsaturated fatty acids suppress the localization and activation of signaling proteins at the immunological synapse in murine CD4+ T cells by affecting lipid raft formation. J Immunol. 2008;181(9):6236–43.
93. Shaikh SR, Rockett BD, Salameh M, Carraway K. Docosahexaenoic acid modifies the clustering and size of lipid rafts and the lateral organization and surface expression of MHC class I of EL4 cells. J Nutr. 2009;139(9):1632–9.
94. Pike LJ. Rafts defined: a report on the keystone symposium on lipid rafts and cell function. J Lipid Res. 2006;47(7):1597–8.
95. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science. 2010;327(5961):46–50.
96. Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta. 2008;1785(2):182–206.
97. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140(6):1807–16.
98. Ma DW, Seo J, Davidson LA, Callaway ES, Fan YY, Lupton JR, et al. n-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon. FASEB J. 2004;18(9):1040–2.
99. Turk HF, Chapkin RS. Membrane lipid raft organization is uniquely modified by n-3 polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2013;88(1):43–7.
100. Fan YY, Ly LH, Barhoumi R, McMurray DN, Chapkin RS. Dietary docosahexaenoic acid suppresses T cell protein kinase Cθ lipid raft recruitment and IL-2 production. J Immunol. 2004;173(10):6151–60.
101. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 2011;12(8):715–23.
102. Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106(2):272–7.
103. Anand BS, Romero JJ, Sanduja SK, Lichtenberger LM. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol. 1999;94(7):1818–22.
104. Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current perspectives in NSAID-induced gastropathy. Mediators Inflamm. 2013;2013:258209.
105. Argoff CE. Recent developments in the treatment of osteoarthritis with NSAIDs. Curr Med Res Opin. 2011;27(7):1315–27.
106. Atkinson TJ, Fudin J, Jahn HL, Kubotera N, Rennick AL, Rhorer M. What’s new in NSAID pharmacotherapy: oral agents to injectables. Pain Med. 2013;14(Suppl 1):S11–7.
107. Medlock S, Eslami S, Askari M, Taherzadeh Z, Opondo D, de Rooij SE, et al. Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: a systematic review of observational studies. Clin Gastroenterol Hepatol. 2013;11(10):1259–69.e10.